International journal of antimicrobial agents · 2019
Treatment of bone and joint infections caused by Enterobacter cloacae with a fluoroquinolone-cotrimoxazole combination.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cisse Hawa, Vernet-Garnier Véronique, Hentzien Maxime, Bajolet Odile, Lebrun Delphine, Bonnet Morgane, Ohl Xavier, Diallo Saidou, Bani-Sadr Firouzé
Аннотация
Although the frequency of bone and joint infections caused by Enterobacter spp. is increasing, studies regarding the optimal antibiotic therapy are scarce. The objective of this retrospective study was to assess the clinical outcomes and safety of a fluoroquinolone-cotrimoxazole combination for the treatment of bone and joint infections caused by Enterobacter cloacae. Between 2010 and 2017, 30 patients with bone and joint infections caused by E. cloacae were treated with a fluoroquinolone-cotrimoxazole combination for 8-12 weeks. There were 26 cases (87%) of infection of an internal fixation device, two cases (6.6%) of pseudarthrosis with chronic osteomyelitis, and two cases (6.6%) of infection of knee and ankle prosthetic devices. The cure rate of the fluoroquinolone-cotrimoxazole combination was 80% by intention-to-treat analysis, with a mean follow-up of 29.3 ± 19.1 months. The fluoroquinolone-cotrimoxazole combination for 8-12 weeks is effective for the treatment of bone and joint infections caused by E. cloacae.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsArthritisDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsEnterobacter cloacaeEnterobacteriaceae InfectionsFemaleFluoroquinolonesHumansMaleMiddle AgedOsteomyelitisProsthesis-Related InfectionsRetrospective StudiesTreatment OutcomeTrimethoprim, Sulfamethoxazole Drug CombinationYoung Adult